The Unified Patient Network expects pharmaceutical companies to sponsor whole-genome sequencing for patients from health systems for research and clinical purposes.
With their strategic partnership, the bioinformatics firms seek to "break the biomarker bottleneck" that is holding back the potential of multi-omics research.
